Foghorn Therapeutics CEO Adrian Gottschalk explains how Foghorn is demonstrating the “beauty of thinking big” as the company applies the power of its Gene Traffic Control platform to advance a pipeline of therapies to address many types of cancer. More from Flagship @ JPM2025 here.
Related Companies
- Foghorn Therapeutics Founded: 2016
